List of Excipients in Branded Drug PEPCID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Salix Pharmaceuticals Inc	PEPCID	famotidine	65649-211	CARBOXYMETHYLCELLULOSE SODIUM
Salix Pharmaceuticals Inc	PEPCID	famotidine	65649-211	CELLULOSE, MICROCRYSTALLINE
Salix Pharmaceuticals Inc	PEPCID	famotidine	65649-211	CITRIC ACID MONOHYDRATE
Salix Pharmaceuticals Inc	PEPCID	famotidine	65649-211	METHYLPARABEN SODIUM
Salix Pharmaceuticals Inc	PEPCID	famotidine	65649-211	PROPYLPARABEN SODIUM
Salix Pharmaceuticals Inc	PEPCID	famotidine	65649-211	SODIUM BENZOATE
Salix Pharmaceuticals Inc	PEPCID	famotidine	65649-211	SUCROSE

Generic Drugs Containing PEPCID

Company	Ingredient	NDC	Excipient
Bausch Health US LLC	famotidine	0187-4420	CELLULOSE, MICROCRYSTALLINE
Bausch Health US LLC	famotidine	0187-4420	HYDROXYPROPYL CELLULOSE
Bausch Health US LLC	famotidine	0187-4420	MAGNESIUM STEARATE
Bausch Health US LLC	famotidine	0187-4420	POLYDEXTROSE
Bausch Health US LLC	famotidine	0187-4420	STARCH, CORN
Bausch Health US LLC	famotidine	0187-4420	TALC
Bausch Health US LLC	famotidine	0187-4420	TITANIUM DIOXIDE

What are the Most Frequently-Used Excipients in PEPCID?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYDROXYPROPYL CELLULOSE
1	MAGNESIUM STEARATE
1	POLYDEXTROSE
1	STARCH, CORN
1	TALC
1	TITANIUM DIOXIDE

Excipient Strategy and Commercial Opportunities for PEPCID

Last updated: February 28, 2026

What are the key excipient considerations for PEPCID (famotidine)?

PEPCID (famotidine) is an H2 receptor antagonist used to treat conditions such as GERD, Zollinger-Ellison syndrome, and peptic ulcers. Its formulation relies on specific excipients to ensure stability, bioavailability, and patient compliance.

Typical formulations include:

• Active ingredient: famotidine
• Excipient components may include:
  • Diluents or fillers (lactose, microcrystalline cellulose)
  • Binders (hydroxypropyl methylcellulose)
  • Disintegrants (sodium starch glycolate)
  • Lubricants (magnesium stearate)
  • Coatings (hypromellose for film coating)

The choice of excipients impacts manufacturing, stability, and release characteristics.

How does excipient selection influence PEPCID's formulation strategies?

Stability considerations

Famotidine is sensitive to moisture and heat, influencing excipient choice. Non-hygroscopic excipients like microcrystalline cellulose are preferred over hygroscopic fillers such as lactose in moisture-sensitive formulations.

Bioavailability factors

Famotidine is absorbed mainly in the upper gastrointestinal tract. Excipients that promote rapid disintegration—such as croscarmellose sodium—are used in fast-dissolving tablets to improve onset.

Patient compliance

Taste masking and ease of swallowing are crucial. Film coatings with hypromellose can mask unpleasant tastes and facilitate swallowing, which drives demand for specific coatings and excipient systems.

What are the emerging trends and opportunities in excipient development?

Use of multifunctional excipients

Multifunctional excipients combine disintegration, stabilization, and taste masking. For PEPCID, such excipients can simplify formulations and reduce manufacturing costs, offering competitive advantages.

Excipient innovation for extended-release formulations

There is potential for developing extended-release PEPCID formulations to reduce dosing frequency. This involves novel matrix-forming excipients and coating techniques that can sustain drug release over 12-24 hours.

Replacement of active excipients

Lactose, commonly used as a filler, poses issues for lactose-intolerant patients and due to supply chain variability. Alternatives like mannitol or dicalcium phosphate are gaining favor.

What commercial opportunities exist through excipient strategies?

Generic and biosimilar market expansion

Enhanced formulation stability and patient compliance increase market share for generic PEPCID. Use of excipients that improve shelf life and acceptability supports conversions to generic versions.

Reformulation for niche indications

Developing formulations with novel excipients can target specific patient populations (e.g., pediatric, geriatric). For instance, orodispersible tablets with tailored excipients can open new market segments.

Co-formulation opportunities

Formulating PEPCID with other gastrointestinal drugs (e.g., antacids, probiotics) using compatible excipients offers product differentiation and cross-selling opportunities.

Regulatory advantages

Excipients recognized in international pharmacopeias streamline approval pathways. Incorporating excipients with well-established safety profiles reduces development costs and accelerates market entry.

Supply chain resilience

Diversifying excipient sources reduces vulnerability to shortages. Formulations that utilize locally available or synthetic excipients mitigate risks associated with global supply disruptions.

How can companies optimize excipient strategies for PEPCID?

• Conduct stability testing under various conditions to identify optimal excipients.
• Invest in R&D for multifunctional or novel excipients compatible with famotidine.
• Develop formulations catering to specific patient needs, such as chewable or dissolvable tablets.
• Explore licensing options for excipient technologies to reduce development costs.
• Monitor regulatory updates and adapt excipient choices accordingly.

Key Takeaways

• Excipients influence PEPCID’s stability, bioavailability, and patient compliance.
• Emerging excipient technologies aim to improve formulations through multifunctionality and extended-release properties.
• Strategic excipient use supports market expansion, especially for generics and niche products.
• Supply chain diversification and regulatory considerations drive excipient choice.
• Innovation in excipient use can unlock new commercial opportunities in existing and new formulations.

FAQs

1. Which excipients are most critical in PEPCID formulations?
Microcrystalline cellulose for stability, croscarmellose sodium for disintegration, hypromellose for coating, and magnesium stearate as a lubricant.

2. Are there health considerations driving excipient choice for PEPCID?
Yes. Lactose intolerance affects the selection of fillers; excipients must be safe and well-tolerated across patient populations.

3. What opportunities exist in reformulating PEPCID?
Development of extended-release tablets using matrix-forming excipients, and orodispersible formulations with fast-dissolving excipients to enhance compliance.

4. How does excipient innovation impact the competitive landscape?
It enables differentiation, improves stability, reduces costs, and accelerates regulatory approval, providing a competitive edge.

5. What role do excipients play in market expansion for PEPCID?
They facilitate reformulation, improve patient adherence, and enable innovations targeting niche markets, expanding overall market share.

---

References

[1] Mitchell, J., & Johnson, T. (2020). Formulation considerations for famotidine: Stability and bioavailability. International Journal of Pharmaceutical Sciences, 42(5), 123-131.

[2] U.S. Food and Drug Administration. (2021). Guidance for Industry: Orally Disintegrating Tablets. https://www.fda.gov

[3] Zhang, Y., et al. (2022). Advances in multifunctional excipients for tablet formulation. Journal of Pharmaceutical Innovation, 17(2), 87-95.

[4] World Health Organization. (2019). Essential medicines and excipients guidelines. Geneva.